EMA Accepts AstraZeneca’s Application for Lung Cancer Biologic
AstraZeneca is seeking approval for its anti-cancer monoclonal antibody, Imfinzi, for treating non-small cell lung cancer in the European Union.
The European Medicines Agency has accepted a marketing authorization application filed by AstraZeneca and MedImmune, AstraZeneca’s biologics research and development arm, seeking approval for Imfinzi (durvalumab) in treating non-small cell lung cancer (NSCLC), the companies announced on Oct. 9, 2017. This marks the first registrational submission for Imfinzi in the European Union, according to the companies.
The companies are specifically seeking marketing authorization for treating locally-advanced (Stage III), unresectable NSCLC in patients whose disease has not progressed following platinum-based chemoradiation therapy.
Imfinzi is a human monoclonal antibody (mAb) that blocks programmed death-L1 (PD-L1) interaction with PD-1 and CD80 on T cells and induces an immune response to tumors. It was approved in the US by FDA in May 2017 for treating locally advanced or metastatic urothelial carcinoma.
The biologic is also being investigated for the adjuvant treatment of NSCLC, for first-line treatment as monotherapy and/or in combination with tremelimumab, an anti-CTLA-4 mAb, for treating metastatic NSCLC.
Source: AstraZeneca
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
